-
公开(公告)号：US20110172928A1
公开(公告)日：2011-07-14
申请号：US12999406
申请日：2009-06-16
IPC分类号： G06F19/00
CPC分类号： C12Q1/6886 , C12Q2600/112 , C12Q2600/118 , C12Q2600/136 , G16B20/00 , G16B25/00 , G16B40/00
摘要： The present invention relates to methods for prediction of an outcome of neoplastic disease or cancer. More specifically, the present invention relates to a method for the prediction of breast cancer by determining in a biological sample from said patient an expression level of a plurality of genes selected from the group consisting of ACTG1, CA12, CALM2, CCND1, CHPT1, CLEC2B, CTSB, CXCL13, DCN, DHRS2, EIF4B, ERBB2, ESR1, FBXO28, GABRP, GAPDH, H2AFZ, IGFBP3, IGHG1, IGKC, KCTD3, KIAA0101, KRT17, MLPH, MMP1, NAT1, NEK2, NR2F2, OAZ1, PCNA, PDLIM5, PGR, PPIA, PRC1, RACGAP1, RPL37A, SOX4, TOP2A, UBE2C and VEGF.
摘要翻译： 本发明涉及用于预测肿瘤性疾病或癌症的结果的方法。 更具体地，本发明涉及通过在来自所述患者的生物样品中测定多种选自ACTG1，CA12，CALM2，CCND1，CHPT1，CLEC2B的多种基因的表达水平来预测乳腺癌的方法 ，CTSB，CXCL13，DCN，DHRS2，EIF4B，ERBB2，ESR1，FBXO28，GABRP，GAPDH，H2AFZ，IGFBP3，IGHG1，IGKC，KCTD3，KIAA0101，KRT17，MLPH，MMP1，NAT1，NEK2，NR2F2，OAZ1，PCNA，PDLIM5 ，PGR，PPIA，PRC1，RACGAP1，RPL37A，SOX4，TOP2A，UBE2C和VEGF。
-
2.发明申请ALGORITHMS FOR OUTCOME PREDICTION IN PATIENTS WITH NODE-POSITIVE CHEMOTHERAPY-TREATED BREAST CANCER 审中-公开患有结直肠癌治疗乳腺癌的患者的预后预测方法公开(公告)号：US20110166838A1
公开(公告)日：2011-07-07
申请号：US12999522
申请日：2009-06-16
IPC分类号： G06F7/60
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/112 , C12Q2600/118 , C12Q2600/136 , C12Q2600/158 , G16B20/00 , G16B25/00 , G16B40/00
摘要： The invention relates to methods for predicting an outcome of cancer in a patient suffering from cancer, said patient having been previously diagnosed as node positive and treated with cytotoxic chemotherapy, said method comprising determining in a biological sample from said patient an expression level of a plurality of genes selected from the group consisting of ACTG1, CAl2, CALM2, CCND1, CHPT1, CLEC2B, CTSB, CXCL13, DCN, DHRS2, EIF4B, ERBB2, ESR1, FBXO28, GABRP, GAPDH, H2AFZ, IGFBP3, IGHG1, IGKC, KCTD3, KIAA0101, KRT17, MLPH, MMP1, NAT1, NEK2, NR2F2, OAZ1, PCNA, PDLIM5, PGR, PPIA, PRC1, RACGAP1, RPL37A, SOX4, TOP2A, UBE2C and VEGF; ABCB1, ABCG2, ADAM15, AKR1C1, AKR1C3, AKT1, BANF1, BCL2, BIRC5, BRMS1, CASP10, CCNE2, CENPJ, CHPT1, EGFR, CTTN, ERBB3, ERBB4, FBLN1, FIP1L1, FLT1, FLT4, FNTA, GATA3, GSTP1, Herstatin, IGF1R, IGHM, KDR, KIT, CKRT5, SLC39A6, MAPK3, MAPT, MKI67, MMP7, MTA1, FRAP1, MUC1, MYC, NCOA3, NFIB, OLFM1, TP53, PCNA, PI3K, PPERLD1, RAB31, RAD54B, RAF1, SCUBE2, STAU, TINF2, TMSL8, VGLL1, TRA@, TUBA1, TUBB, TUBB2A.
摘要翻译： 本发明涉及用于预测患有癌症的患者的癌症结果的方法，所述患者先前被诊断为淋巴结阳性并用细胞毒性化疗治疗，所述方法包括在来自所述患者的生物样品中确定多个表达水平 选自ACTG1，CA2，CALM2，CCND1，CHPT1，CLEC2B，CTSB，CXCL13，DCN，DHRS2，EIF4B，ERBB2，ESR1，FBXO28，GABRP，GAPDH，H2AFZ，IGFBP3，IGHG1，IGKC，KCTD3， KIAA0101，KRT17，MLPH，MMP1，NAT1，NEK2，NR2F2，OAZ1，PCNA，PDLIM5，PGR，PPIA，PRC1，RACGAP1，RPL37A，SOX4，TOP2A，UBE2C和VEGF; ABCB1，ABCG2，ADAM15，AKR1C1，AKR1C3，AKT1，BANF1，BCL2，BIRC5，BRMS1，CASP10，CCNE2，CENPJ，CHPT1，EGFR，CTTN，ERBB3，ERBB4，FBLN1，FIP1L1，FLT1，FLT4，FNTA，GATA3，GSTP1， Herbatin，IGF1R，IGHM，KDR，KIT，CKRT5，SLC39A6，MAPK3，MAPT，MKI67，MMP7，MTA1，FRAP1，MUC1，MYC，NCOA3，NFIB，OLFM1，TP53，PCNA，PI3K，PPERLD1，RAB31，RAD54B，RAF1， SCUBE2，STAU，TINF2，TMSL8，VGLL1，TRA @，TUBA1，TUBB，TUBB2A。
-
公开(公告)号：US20120053842A9
公开(公告)日：2012-03-01
申请号：US12999406
申请日：2009-06-16
IPC分类号： G06F19/00
CPC分类号： G06F19/24 , C12Q1/6886 , C12Q2600/112 , C12Q2600/118 , C12Q2600/136 , G06F19/18 , G06F19/20
摘要： The present invention relates to methods for prediction of an outcome of neoplastic disease or cancer. More specifically, the present invention relates to a method for the prediction of breast cancer by determining in a biological sample from said patient an expression level of a plurality of genes selected from the group consisting of ACTG1, CA12, CALM2, CCND1, CHPT1, CLEC2B, CTSB, CXCL13, DCN, DHRS2, EIF4B, ERBB2, ESR1, FBXO28, GABRP, GAPDH, H2AFZ, IGFBP3, IGHG1, IGKC, KCTD3, KIAA0101, KRT17, MLPH, MMP1, NAT1, NEK2, NR2F2, OAZ1, PCNA, PDLIM5, PGR, PPIA, PRC1, RACGAP1, RPL37A, SOX4, TOP2A, UBE2C and VEGF.
摘要翻译： 本发明涉及用于预测肿瘤性疾病或癌症的结果的方法。 更具体地，本发明涉及通过在来自所述患者的生物样品中测定多种选自ACTG1，CA12，CALM2，CCND1，CHPT1，CLEC2B的多种基因的表达水平来预测乳腺癌的方法 ，CTSB，CXCL13，DCN，DHRS2，EIF4B，ERBB2，ESR1，FBXO28，GABRP，GAPDH，H2AFZ，IGFBP3，IGHG1，IGKC，KCTD3，KIAA0101，KRT17，MLPH，MMP1，NAT1，NEK2，NR2F2，OAZ1，PCNA，PDLIM5 ，PGR，PPIA，PRC1，RACGAP1，RPL37A，SOX4，TOP2A，UBE2C和VEGF。
-
公开(公告)号：US20130065786A1
公开(公告)日：2013-03-14
申请号：US13638360
申请日：2011-03-29
申请人： Mareike Dartmann , Inke Sabine Feder , Mathias Gehrmann , Guido Hennig , Karsten Weber , Christian Von Törne , Ralf Kronenwett , Christoph Petry
发明人： Mareike Dartmann , Inke Sabine Feder , Mathias Gehrmann , Guido Hennig , Karsten Weber , Christian Von Törne , Ralf Kronenwett , Christoph Petry
CPC分类号： C12Q1/6886 , C12Q2600/118 , C12Q2600/158
摘要： The present invention relates to methods, kits and systems for the prognosis of the disease outcome of breast cancer, said method comprising: (a) determining in a tumor sample from said patient the RNA expression levels of at least 2 of the following 9 genes: UBE2C, BIRC5, RACGAP1, DHCR7, STC2, AZGP1, RBBP8, IL6ST, and MGP (b) mathematically combining expression level values for the genes of the said set which values were determined in the tumor sample to yield a combined score, wherein said combined score is indicative of a prognosis of said patient; and kits and systems for performing said method.
摘要翻译： 本发明涉及用于乳腺癌疾病预后的方法，试剂盒和系统，所述方法包括：（a）在所述患者的肿瘤样品中测定以下9个基因中至少2个的RNA表达水平： UBE2C，BIRC5，RACGAP1，DHCR7，STC2，AZGP1，RBBP8，IL6ST和MGP（b）在数学上组合所述组的基因的表达水平值，其在肿瘤样品中测定以产生组合评分，其中所述组合 评分表示所述患者的预后; 以及用于执行所述方法的套件和系统。
-
公开(公告)号：US20090311700A1
公开(公告)日：2009-12-17
申请号：US12441748
申请日：2007-09-25
CPC分类号： C12Q1/6886 , C12Q2600/112 , C12Q2600/118
摘要： The present invention relates to methods, kits and systems for the prognosis of the disease outcome of breast cancer in untreated breast cancer patients. More specific, the present invention relates to the prognosis of breast cancer based on measurements of the expression levels of marker genes in tumor samples of breast cancer patients. Marker genes are disclosed which allow for an accurate prognosis of breast cancer in patients having node negative, fast proliferating breast cancer.
摘要翻译： 本发明涉及未经治疗的乳腺癌患者乳腺癌预后的方法，试剂盒和系统。 更具体地说，本发明是基于乳腺癌患者肿瘤样本中标记基因表达水平的测定，涉及乳腺癌的预后。 公开了标记基因，其允许在具有淋巴结阴性，快速增殖的乳腺癌的患者中对乳腺癌的准确预后。
-
公开(公告)号：US20090239223A1
公开(公告)日：2009-09-24
申请号：US12307590
申请日：2007-07-06
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/158
摘要： The invention relates to methods and kits for the prediction of a likely outcome of chemotherapy in a cancer patient. More specifically, the invention relates to the prediction of tumour response to chemotherapy based on measurements of expression levels of a small set of marker genes. The set of marker genes is useful for the identification of breast cancer subtypes responsive to taxane based chemotherapy, such as e.g. a taxane-anthracycline-cyclophosphamide-based (e.g. Taxotere (docetaxel)-Adriamycin (doxorubicin)-cyclophosphamide, i.e. (TAC)-based) chemotherapy.
摘要翻译： 本发明涉及用于预测癌症患者化学疗法可能结果的方法和试剂盒。 更具体地，本发明涉及基于对一小组标记基因的表达水平的测量来预测肿瘤对化学疗法的反应。 该组标记基因可用于鉴定对基于紫杉烷的化学疗法有效的乳腺癌亚型，例如， 紫杉烷 - 蒽环类 - 环磷酰胺（如泰索帝（多西紫杉醇） - 阿霉素（多柔比星） - 环磷酰胺，即（TAC））化疗。
-
公开(公告)号：US20090222387A1
公开(公告)日：2009-09-03
申请号：US11922276
申请日：2006-06-14
IPC分类号： G06F15/18
摘要： The present invention relates to methods and compositions for the diagnosis, prognosis, and prediction of breast cancer. More specifically, the invention relates to classification of breast cancer tissue samples based on measuring the expression of a set of marker genes. The set is useful for the identification of clinically important breast cancer subtypes. Methods are disclosed for prediction, diagnosis and prognosis of breast cancer.
摘要翻译： 本发明涉及用于乳腺癌诊断，预后和预测的方法和组合物。 更具体地，本发明涉及基于测量一组标记基因的表达的乳腺癌组织样品的分类。 该组对于鉴定临床重要的乳腺癌亚型是有用的。 公开了乳腺癌预测，诊断和预后的方法。
-
8.发明申请公开(公告)号：US20140228241A1
公开(公告)日：2014-08-14
申请号：US14235168
申请日：2012-07-30
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q1/6809 , C12Q2600/106 , C12Q2600/118 , C12Q2600/158 , C12Q2600/178
摘要： A method for predicting a response to and/or benefit of chemotherapy, including neoadjuvant chemotherapy, in a patient suffering from or at risk of developing recurrent neoplastic disease, in particular breast cancer, said method comprising the steps of: (a) determining in a tumor sample from said patient the RNA expression levels of the following 8 genes: UBE2C, RACGAP1, DHCR7, STC2, AZGP1, RBBP8, IL6ST, and MGP, indicative of a response to chemotherapy for a tumor, or (b) determining in a tumor sample from said patient the RNA expression levels of the following 8 genes: UBE2C, BIRC5, DHCR7, STC2, AZGP1, RBBP8, IL6ST, and MGP; indicative of a response to chemotherapy for a tumor (c) mathematically combining expression level values for the genes of the said set which values were determined in the tumor sample to yield a combined score, wherein said combined score is predicting said response and/or benefit of chemotherapy.
摘要翻译： 一种在患有或有发生复发性肿瘤疾病，特别是乳腺癌风险的患者中预测化疗（包括新辅助化疗）的反应和/或益处的方法，所述方法包括以下步骤：（a）在 来自所述患者的肿瘤样品包括以下8个基因：UBE2C，RACGAP1，DHCR7，STC2，AZGP1，RBBP8，IL6ST和MGP的RNA表达水平，其指示对肿瘤的化学疗法的反应，或（b）在肿瘤中测定 来自所述患者的样品来自以下8个基因的RNA表达水平：UBE2C，BIRC5，DHCR7，STC2，AZGP1，RBBP8，IL6ST和MGP; 指示对肿瘤的化学疗法的反应（c）在数学上组合所述组的基因的表达水平值，所述基因在肿瘤样品中测定以产生组合评分，其中所述组合评分预测所述应答和/或益处 的化疗。
-
9.发明申请公开(公告)号：US20110143946A1
公开(公告)日：2011-06-16
申请号：US12674782
申请日：2008-08-25
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/112 , C12Q2600/158
摘要： The present invention relates to a method for predicting a response of a tumor in a patient suffering from or at risk of developing recurrent gynecologic cancer towards a chemotherapeutic agent, said method comprising the steps of: a) obtaining a biological sample from said patient; b) determining the pattern of expression level of at least one gene of the group comprising AKR1C1, MLPH, ESR1, PGR, COMP, DCN, IGKC, CCL5, FBN1 and/or UBE2C, or of genes coregulated therewith, in said sample; c) comparing the pattern of expression levels determined in (b) with one or several reference pattern (s) of expression levels; d) identifying at least one marker gene; e) determining a molecular subtype for said sample on the basis of (d); and f) predicting from said molecular subtype response of a tumor for a chemotherapeutic agent, wherein the molecular subtype is selected from the group comprising the subtypes basal, stromal-high, stromal-low, luminal A, immune system-high, immune system-low, proliferation-high and/or proliferation-low.
摘要翻译： 本发明涉及一种用于预测患有或具有针对化疗剂的复发性妇科癌的风险的患者中的肿瘤的反应的方法，所述方法包括以下步骤：a）从所述患者获得生物样品; b）确定所述样品中包含AKR1C1，MLPH，ESR1，PGR，COMP，DCN，IGKC，CCL5，FBN1和/或UBE2C或与其结合的基因的组的至少一个基因的表达水平的模式; c）比较（b）中确定的表达水平与一种或几种表达水平的参考模式的模式; d）鉴定至少一个标记基因; e）基于（d）确定所述样品的分子亚型; 以及f）从所述化学治疗剂的肿瘤的分子亚型应答预测其中所述分子亚型选自基础基质，基质高，基质低，管腔A，免疫系统高免疫系统的亚型， 低，增殖高和/或增殖低。
-
公开(公告)号：US20090130678A1
公开(公告)日：2009-05-21
申请号：US12095922
申请日：2006-11-23
IPC分类号： C12Q1/68 , C12Q1/02 , G01N33/574 , C40B30/00
CPC分类号： G01N33/57415 , C12Q1/6886 , C12Q2600/112 , C12Q2600/118 , G01N2333/91215
摘要： The present invention relates to the field of prognosis of a proliferative disease in a patient. More specifically, the present invention relates to methods for the identification of the likely outcome of breast cancer in a breast cancer patient. The invention also relates to methods for the identification of the likely outcome of breast cancer in a patient on the basis of the ERBB2 status of the patient and expression levels of immune genes in tumour tissue of said patient.
摘要翻译： 本发明涉及患者中增殖性疾病的预后领域。 更具体地，本发明涉及用于鉴定乳腺癌患者乳腺癌的可能结果的方法。 本发明还涉及基于患者的ERBB2状态和所述患者的肿瘤组织中的免疫基因的表达水平来鉴定患者中乳腺癌的可能结果的方法。
-
-
-
-
-
-
-
-
-
搜索结果
21 条记录 (耗时 0.03 秒)
